Navigation Links
Gene Variant Protects Black Heart Failure Patients
Date:4/21/2008

Has same effect as beta blocker drugs in 40% of blacks, study finds

MONDAY, April 21 (HealthDay News) -- Researchers have discovered a gene variant carried by about 40 percent of blacks that protects them after heart failure as much as widely used beta blocker drugs do.

The finding explains the puzzling results reported in trials of beta blocker therapy in black people, said Dr. Stephen B. Liggett, a professor of medicine and physiology at the University of Maryland, and co-author of a report in the April 20 online issue of Nature Medicine.

"To our knowledge, this is the first case where a genetic variant mimics the activity of a drug used to treat a disease," Liggett said.

But Liggett predicted "further surprises" along the same lines as research on human genetic variations continues.

The finding won't have an immediate effect on treatment of heart failure, the progressive loss of ability to pump blood that affects an estimated 5 million Americans, said study co-author Dr. Gerald W. Dorn II, director of the Center for Pharmacogenomics at Washington University in St. Louis. Doctors can continue to prescribe beta blockers for people with heart failure, black or white, since the drugs have little risk, he said.

But there should be an effect on future medical practice, Dorn said. "One idea in the future of drug discovery is that we will not only need to tailor therapy for individual genetic makeup but also take genetic makeup into consideration in drug testing," he explained.

About 2 percent to 3 percent of white Americans in the total group of 2,000 who were tested carried the gene variant, he said.

The research finding was made possible by the Human Genome Project, which laid out all the more than 20,000 genes that act in humans. The researchers zeroed in on the gene pathway responsible for the activity of adrenaline, a hormone that increases cardiac output. In heart failure, the adrenal glands produce more and more adrenaline to increase blood flow. Overproduction of adrenaline causes the heart to weaken faster. Beta blockers ease the pressure on the heart by blocking adrenaline receptors in heart muscle.

The researchers looked at two genes in the adrenaline pathway, GRK2 and GRK5. They found one specific variant, designated GRK5-Leu41, that reduced the effect of adrenaline on heart cells. A study of 375 black adults with heart failure showed that among those not taking beta blockers, those with the GRK5-Leu41 variant lived twice as long as those with the more common variant. The same prolonged survival was seen in those with the normal variant who took beta blockers. Beta blocker therapy did not increase the survival of individuals with the helpful gene variant.

The same kind of genetic analysis will inevitably be extended to other drugs and other diseases, Liggett said.

"Our idea is not to replace the physician's judgment, but to give a handle on which drugs they might want to push to higher levels and which are less likely to be helpful for specific individuals," he said.

More information

Heart failure and its treatment are described by the U.S. National Library of Medicine.



SOURCES: Stephen B. Liggett, M.D., professor, medicine and physiology, University of Maryland, Baltimore; Gerald W. Dorn II, M.D., director, Center for Pharmacogenomics, Washington University, St. Louis; April 20, 2008, Nature Medicine online


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Gene Variants Linked to Lung Cancer Identified
2. Gene Variants Can Predict Threat of Heart Disease
3. Gene variant predicts medication response in patients with alcohol dependence
4. Gene variant linked to moderated symptoms of beta-thalassemia
5. Gene Variant Tied to More Aggressive Prostate Cancer
6. Gene Variant Doubles Risk of Prostate Cancer in Black Men
7. Scientists discover genetic variant associated with prostate cancer in African Americans
8. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
9. New Drug Protects Against Radiation Damage
10. Injectable Antibiotic Protects Against Lyme Disease in Mice
11. Fasting Before Chemo Protects Healthy Cells
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene Variant Protects Black Heart Failure Patients
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology: